首页> 美国卫生研究院文献>Journal of Hematology Oncology >Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

【2h】

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

机译：在III期ASPIRE研究中使用卡非佐米来那度胺和地塞米松（KRd）与来那度胺和地塞米松（Rd）治疗的复发性多发性骨髓瘤患者根据计划的治疗持续时间无应答和无进展生存

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundIn ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma. Per protocol, patients received KRd for a maximum of 18 cycles followed by Rd to progression, so the benefit/risk profile of KRd to progression was not established.

机译：背景在ASPIRE中，与来那度胺和地塞米松（Rd）相比，卡非佐米，来那度胺和地塞米松（KRd）显着改善了复发性多发性骨髓瘤患者的无进展生存期（PFS）和缓解率。根据方案，患者接受KRd最多18个周期，然后再进行Rd进行进展，因此未确定KRd进行进展的获益/风险状况。

著录项

期刊名称 Journal of Hematology Oncology
作者
Meletios Dimopoulos; Michael Wang; Vladimir Maisnar; Jiri Minarik; William Bensinger; Maria-Victoria Mateos; Mihaela Obreja; Julie Blaedel; Philippe Moreau;
展开▼
作者单位

展开▼
年(卷),期 2018(11),-1
年度 2018
页码 49
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;血液学检验;
关键词
Clinical research Clinical trials Multiple myeloma Myeloma therapy;

机译：临床研究;临床试验;多发性骨髓瘤;骨髓瘤治疗;

相似文献

外文文献
中文文献
专利

1. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma [J] . Stewart A. Keith, Dimopoulos Meletios A., Masszi Tamas, Journal of Clinical Oncology . 2016,第32期

机译：评估卡非佐米，来那度胺和地塞米松与来那度胺和地塞米松在复发性多发性骨髓瘤患者中的开放标签，随机，III期ASPIRE试验与健康相关的生活质量结果
2. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation: Secondary Analysis from the Phase 3 Aspire Study (NCT01080391) [J] . Hari Parameswaran N., Song Kevin, Bensinger William, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第3Suppla1期

机译：卡非佐米，来那度胺和地塞米松与来那度胺和地塞米松对自体干细胞移植后复发性多发性骨髓瘤患者的疗效和安全性：3期Aspire研究的二级分析（NCT01080391）
3. Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyeLome (IFM) Krd Phase II Study [J] . Roussel Murielle, Lauwers-Cances Valerie, Robillard Nelly, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：卡非佐米，来那度胺和地塞米松（KRd）诱导的一线治疗，然后是新诊断的多发性骨髓瘤（NDMM）患者的自体干细胞移植，Krd合并和来那度胺维持：组间法语国语双歧双歧（IFM）Krd II期研究的主要结果
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Health-Related Quality-of-Life Results From the Open-Label Randomized Phase III ASPIRE Trial Evaluating Carfilzomib Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma [O] . A. Keith Stewart, Meletios A. Dimopoulos, Tamás Masszi, -1

机译：评估卡非佐米来那度胺和地塞米松与来那度胺和地塞米松在复发性多发性骨髓瘤患者中的开放标签随机III期ASPIRE试验与健康相关的生活质量结果
6. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study [O] . Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, 2018

机译：根据患有用Carfilzomib，Lenalymide和Dexamethasone（KRD）的多发性骨髓瘤患者的计划治疗持续时间的反应和无进展生存期与III期Aspire Chinain的Lenalalomide（KRD）与番醇胺和地塞米松（RD）进行了近期骨髓瘤

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅